{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:08:34Z","timestamp":1790428114474,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.clgc.2021.04.001","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T10:24:21Z","timestamp":1619000661000},"page":"457-465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial"],"prefix":"10.1016","volume":"19","author":[{"given":"L","family":"Marandino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Raggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Calareso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Alessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Colecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7838-2526","authenticated-orcid":false,"given":"R","family":"Madison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-2596","authenticated-orcid":false,"given":"J S","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-2756","authenticated-orcid":false,"given":"A","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2021.04.001_bib0001","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.eururo.2019.05.037","article-title":"Programmed death-1 or programmed death ligand-1 blockade in patients with platinum-resistant metastatic urothelial cancer: a systematic review and meta-analysis","volume":"76","author":"Niglio","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2021.04.001_bib0002","unstructured":"Necchi A., Marandino L., Raggi D., et\u00a0al. Is it time to consider eliminating surgery from the treatment of locally advanced bladder cancer? [epub ahead of print]. Eur Urol10.1016\/j.eururo.2020.08.022, accessed May 6, 2021."},{"key":"10.1016\/j.clgc.2021.04.001_bib0003","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","article-title":"Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer","volume":"34","author":"Massard","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.04.001_bib0004","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2021.04.001_bib0005","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clgc.2021.04.001_bib0006","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1158\/1535-7163.MCT-18-1399","article-title":"Cabozantinib in combination with immunotherapy for advanced renal cell carcinoma and urothelial carcinoma: rationale and clinical evidence","volume":"18","author":"Bergerot","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clgc.2021.04.001_bib0007","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1470-2045(20)30202-3","article-title":"Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial","volume":"21","author":"Apolo","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2021.04.001_bib0008","doi-asserted-by":"crossref","first-page":"viii303","DOI":"10.1093\/annonc\/mdy283.081","article-title":"Phase 1B study (COSMIC-021) of cabozantinib with atezolizumab: results of the dose escalation stage in patients (pts) with treatment-na\u00efve advanced renal cell carcinoma (RCC)","volume":"29","author":"Agarwal","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2021.04.001_bib0009","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1200\/JCO.2018.36.6_suppl.515","article-title":"Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies","volume":"36","author":"Nadal","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.04.001_bib0010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.2020.38.6_suppl.139","article-title":"Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): results of Cohort 6 of the COSMIC-021 Study","volume":"38","author":"Agarwal","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.04.001_bib0011","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1200\/JCO.2020.38.4_suppl.478","article-title":"Nivolumab (NIVO)\u00a0+\u00a0ipilimumab (IPI)\u00a0+\u00a0cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040","volume":"38","author":"Yau","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.04.001_bib0012","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1200\/JCO.2020.38.15_suppl.5013","article-title":"Cabozantinib in combination with atezolizumab in urothelial carcinoma previously treated with platinum-containing chemotherapy: results from cohort 2 of the COSMIC-021 study","volume":"38","author":"Pal","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.04.001_bib0013","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/annonc\/mdv509","article-title":"Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis","volume":"27","author":"Raggi","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2021.04.001_bib0014","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2021.04.001_bib0015","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2021.04.001_bib0016","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.clgc.2021.04.001_bib0017","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome MED"},{"key":"10.1016\/j.clgc.2021.04.001_bib0018","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jmoldx.2018.05.004","article-title":"Analytical validation of a hybrid capture-based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA","volume":"20","author":"Clark","year":"2018","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.clgc.2021.04.001_bib0019","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/nar\/gku1075","article-title":"COSMIC: exploring the world's knowledge of somatic mutations in human cancer","volume":"43","author":"Forbes","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.clgc.2021.04.001_bib0020","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jmoldx.2019.06.011","article-title":"A novel next-generation sequencing approach to detecting microsatellite instability and pan-tumor characterization of 1000 microsatellite instability-high cases in 67,000 patient samples","volume":"21","author":"Trabucco","year":"2019","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.clgc.2021.04.001_bib0021","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(19)30668-0","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial","volume":"21","author":"Petrylak","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2021.04.001_bib0022","unstructured":"AstraZeneca. Update on phase III Danube trial for Imfinzi and tremelimumab in unresectable, stage IV bladder cancer. Available at: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2020\/update-on-phase-iii-danube-trial-for-imfinzi-and-tremelimumab-in-unresectable-stage-iv-bladder-cancer-06032020.html. Accessed: July 13, 2020."},{"key":"10.1016\/j.clgc.2021.04.001_bib0023","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","article-title":"Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial","volume":"17","author":"Drilon","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2021.04.001_bib0024","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2159-8290.CD-13-0035","article-title":"Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas","volume":"3","author":"Drilon","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clgc.2021.04.001_bib0025","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.04.001_bib0026","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.clgc.2021.04.001_bib0027","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.04.001_bib0028","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/annonc\/mdx479","article-title":"Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma","volume":"28","author":"Schlumberger","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2021.04.001_bib0029","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/2159-8290.CD-20-0047","article-title":"Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade","volume":"10","author":"Zhang","year":"2020","journal-title":"Cancer Discov"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767321000860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767321000860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:33:58Z","timestamp":1761564838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767321000860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1558767321000860"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2021.04.001","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2021.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}